FrancophonIA/ELRC3.0 huggingface dataset:
English: This is of particular importance because Coxiella burnetii can lead to a disease in humans called Qfever and decreasing the disease in animals will decrease the likelihood of transmitting the disease to humans.
Estonian: See on eriti tähtis põhjusel, et Coxiella burnetii võib tekitada inimestel Q-palavikku ja haiguse tõrjumine loomadel väheneb haiguse ülekandumist inimestele.
English: Nine months later, two additional injections should be given to cattle, again three weeks apart.
Estonian: 9 kuu pärast tuleb veistele teha veel kaks 3-nädalase vahega süsti.
English: What is Coxevac?
Estonian: Mis on Coxevac?
English: In goats it is also very common to observe a slight increase of rectal temperature for 4 days post-vaccination without other general signs.
Estonian: Kitsedel võib 4 päeva jooksul pärast vaktsineerimist samuti veidi tõusta rektaalne temperatuur, kuid muid üldisi nähte ei avaldu.
English: When Coxevac is given to cattle and goats, their immune system recognises the bacteria contained in the vaccine as ‘foreign' and makes antibodies to defend against them.
Estonian: Kui veistele ja kitsedele manustatakse Coxevaci, peab immuunsüsteem vaktsiinis sisalduvaid baktereid võõraks ja tekitab nende vastu antikehi.
English: The studies conducted in cattle and goats showed that Coxevac reduces bacteria shedding (which is a major factor in spreading the disease) in vaginal discharge and milk, whilst in goats Coxevac reduced bacteria shedding in faeces and the placenta as well.
Estonian: Veistel ja kitsedel tehtud efektiivsusuuringute põhjal vähendab Coxevac veistel ja kitsedel bakterite eritumist (mis on haiguse leviku seisukohast ülioluline) tupelimasse ja piima ning vähendab kitsedel bakterite eritumist ka väljaheitesse ja platsentasse.
English: In cattle and goats Q-fever can cause abortions, still births and pneumonia.
Estonian: Veistel ja kitsedel võib Q-palavik põhjustada tiinuse katkemist, surnultsünde ja pneumooniat.
English: Inactivated Coxiella burnetii vaccine
Estonian: Coxevac inaktiveeritud Coxiella burnetii vaktsiin
English: Coxevac is used in cattle to lower the risk of spreading Coxiella burnetii infection and in goats to reduce abortions caused by the infection as well as reduce spreading the infection.
Estonian: Coxevaci kasutatakse veistel Coxiella burnetii infektsiooni levikuriski vähendamiseks ning kitsedel tiinuse katkemise ja samuti infektsiooni levikuriski vähendamiseks.
English: The disease it causes is known as Q-fever.
Estonian: See põhjustab Q-palavikku.
English: In the future, if the animals are exposed to Coxiella burnetii bacteria, the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad Coxiella burnetii bakteritega hiljem uuesti kokku, tekivad antikehad kiiremini.
English: Why has Coxevac been approved?
Estonian: Miks Coxevac heaks kiideti?
English: What is the risk associated with Coxevac?
Estonian: Mis riskid Coxevaciga kaasnevad?
English: Other information about Coxevac:
Estonian: Muu teave Coxevaci kohta
English: The vaccine is given to cattle and goats from three months of age.
Estonian: Vaktsiini manustatakse vähemalt 3-kuustele veistele ja kitsedele.
English: The studies in goats also showed a lower proportion of abortions in the goats that were vaccinated compared with unvaccinated goats.
Estonian: Kitsede uuringus esines vaktsineeritud kitsedel vähem tiinuse katkemist kui vaktsineerimata kitsedel.
English: What is Coxevac used for?
Estonian: Milleks Coxevaci kasutatakse?
English: Coxevac was initially authorised under ‘exceptional circumstances'.
Estonian: Coxevac on heaks kiidetud erandkorras.
English: The effectiveness of the vaccine in goats has been determined in two field studies with pregnant goats exposed to Coxiella burnettii.
Estonian: Vaktsiini efektiivsus kitsedel määrati kahes väliuuringus, kus tiined kitsed puutusid kokku bakteriga Coxiella burnetii.
English: How has Coxevac been studied?
Estonian: Kuidas Coxevaci uuriti?
English: How does Coxevac work?
Estonian: Kuidas Coxevac toimib?
English: The vaccine is given as two injections under the skin, three weeks apart.
Estonian: Seda süstitakse kahe nahaaluse süstena 3-nädalase vahega.
English: What benefit has Coxevac shown during the studies?
Estonian: Milles seisneb uuringute põhjal Coxevaci kasulikkus?
English: Coxevac is available as a suspension for injection.
Estonian: Coxevaci turustatakse süstesuspensioonina.
English: 448 (4 x 112) capsules
Estonian: 448 (4 x 112) kapslit
English: Capsule, hard bottle (HDPE)
Estonian: Purk (HDPE)
English: Annex A
Estonian: ML number
English: 1 Regulation (EC) No 1394/2007
Estonian: 1 Määrus (EÜ) nr 1394/2007
English: Some of the concerns were linked to the manufacturing process.
Estonian: Mõned küsimused olid seotud ravimi tootmisprotsessiga.
English: EMEA/H/C/002657
Estonian: 21. veebruar 2013 EMA/52320/2013 EMEA/H/C/002657
English: On 14 January 2013, Anika Therapeutics S.r.l.
Estonian: Anika Therapeutics S.r.l.
English: Patients who have any questions should speak to their doctor.
Estonian: Küsimuste korral peaksid patsiendid pöörduma oma raviarsti poole.
English: The main measures of effectiveness were based on the evaluation of patients' cartilage and knee function after treatment.
Estonian: Efektiivsuse põhinäitajad olid patsientide kõhre hindamine ja põlvefunktsioon pärast ravi.
English: Hyalograft C autograft has been used in the following EU countries: Austria, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Lithuania, Poland and Romania, before the introduction of the EU
Estonian: Enne Euroopa Liidu uudsete ravimite määruse vastuvõtmist 2009. aastal1 kasutati Hyalograft C autografti järgmistes Euroopa Liidu liikmesriikides: Austria, Bulgaaria, Itaalia, Kreeka, Leedu, Poola,
English: Overall, the results from studies in patients did not justify the proposed use of the product and its safety could not be ascertained conclusively from the data that had so far been presented.
Estonian: Üldkokkuvõttes ei õigustanud patsiendiuuringute tulemused ravimi väljapakutud kasutamist ja seni esitatud andmete alusel ei olnud võimalik kindlalt veenduda ravimi ohutuses.
English: There were also questions about the way the main studies were conducted, such as the failure to randomly select patients for each treatment group, which led to uncertainties about how the results should be interpreted.
Estonian: Samuti oli küsimusi põhiuuringute läbiviimise kohta, näiteks patsientide mitterandomiseeritud valik ravirühmadesse, mis tekitas kahtlust uuringutulemuste tõlgendamise osas.
English: This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to repair, regenerate or replace tissue.
Estonian: See on koetehnoloogiliselt töödeldud rakke või kudesid sisaldav toode, mida saab kasutada kudede parandamiseks, taastamiseks või asendamiseks.
English: What was the recommendation of the CAT at that time?
Estonian: Milline oli sel ajal uudsete ravimite komitee soovitus?
English: Following this withdrawal, Hyalograft C autograft will no longer be available and healthcare professionals will need to consider other treatment options for patients with femoral cartilage defects.
Estonian: Pärast taotluse tagasivõtmist ei ole Hyalograft C autograft enam kättesaadav ja arstid peavad reieluu kõhre defektidega patsientidel kaaluma muid ravivõimalusi.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that the decision to withdraw the application was based on the outcome of the CAT's preliminary assessment.
Estonian: Kirjas, milles ettevõte teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et otsus taotlus tagasi võtta põhineb uudsete ravimite komitee esialgse hindamise tulemusel.
English: The company had not yet responded to the CAT's questions at the time of the withdrawal.
Estonian: Ettevõte ei olnud taotluse tagasivõtmise ajaks neile küsimustele veel vastanud.
English: The evaluation of advanced therapy products involves an assessment by the Committee for Advanced Therapies (CAT) before an opinion is adopted by the Committee for Medicinal Products for Human Use (CHMP).
Estonian: Uudsete ravimite hindamine hõlmab uudsete ravimite komitee hinnangut, enne kui inimravimite komitee oma arvamuse vastu võtab.
English: Further data on its benefits and safety were being awaited from the company.
Estonian: Ettevõttel paluti esitada ravimi kasulikkuse ja ohutuse toetuseks täiendavaid andmeid.
English: What consequences does this withdrawal have for patients?
Estonian: Kuidas mõjutab müügiloa taotluse tagasivõtmine patsiente?
English: This application was withdrawn after the CAT had assessed the initial documentation provided by the company and had formulated a list of questions.
Estonian: Müügiloa taotlus võeti tagasi pärast seda, kui uudsete ravimite komitee oli hinnanud ettevõtte esialgu esitatud dokumente ja koostanud ettevõttele vastamiseks küsimused.
English: regulation on advanced therapies in 2009.1 Under the regulation, advanced therapies already available in the EU are to undergo an evaluation by the EMA in order to obtain an EU wide marketing authorisation.
Estonian: Selle määruse kohaselt peavad juba Euroopa Liidus kasutatavad uudsed ravimid läbima Euroopa Ravimiameti hindamise, et saada kogu Euroopa Liidus kehtiv müügiluba.
English: It was for use in adults experiencing symptoms caused by sudden or repetitive trauma to the cartilage.
Estonian: Ravimit kavatseti kasutada täiskasvanutel, kellel esinevad kõhre ägedast või kroonilisest traumast tingitud sümptomid.
English: What is Hyalograft C autograft?
Estonian: Mis on Hyalograft C autograft?
English: The cells are then planted on the square inserts, which are used by a surgeon to fill in the spaces on the bone where cartilage has been damaged.
Estonian: Seejärel istutatakse kõhrerakud ruudukujulistele toestele, millega kirurg katab need luualad, kus kõhr on kahjustunud.
English: Hyalograft C autograft is made from chondrocytes (cartilage cells) taken from the patient and grown outside the body.
Estonian: Hyalograft C autograft koosneb patsiendilt võetud kondrotsüütidest (kõhrerakkudest), mida on kasvatatud väljapool organismi.
English: The company informed the EMA that there were no ongoing clinical trials or compassionate use programmes with Hyalograft C autograft at the time of the withdrawal.
Estonian: Ettevõte teatas Euroopa Ravimiametile, et taotluse tagasivõtmise ajal ei olnud Hyalograft C autograftiga pooleli kliinilisi uuringuid ega ravimi eriloaga kasutamise programme.
English: Hyalograft C autograft is an implant consisting of cartilage cells derived from the patient and planted on 2x2 cm square inserts.
Estonian: Hyalograft C autograft on implantaat, mis koosneb patsiendilt võetud kõhrerakkudest, mis on istutatud 2×2 cm suurustele ruudukujulistele toestele.
English: Hyalograft C autograft is a type of advanced therapy product called a ‘tissue engineered product'.
Estonian: Hyalograft C autograft on uudne ravim, mida nimetatakse koetehnoloogiliseks tooteks.
English: At the time of the withdrawal, the CAT had not issued its final recommendation but had some concerns about the data submitted in the application.
Estonian: Müügiloa taotluse tagasivõtmise ajal ei olnud uudsete ravimite komitee oma lõplikku soovitust vastu võtnud, nägi aga esitatud andmetele tuginedes põhjust ettevaatlikkuseks.
English: 21 February 2013
Estonian: Lk 2/2
English: What was Hyalograft C autograft being evaluated for?
Estonian: Mis eesmärgil Hyalograft C autografti hinnati?
English: The main data submitted by the company came from two published studies involving 126 patients with femoral cartilage defects, which compared Hyalograft C autograft with a surgical technique known as microfracture repair.
Estonian: Peamised ettevõtte esitatud andmed põhinesid kahel avaldatud uuringul, milles osales 126 reieluu kõhre defektidega patsienti.
English: Hyalograft C autograft was being evaluated for use in repairing cartilage defects at the end of the femur (the thigh bone), where the bone forms part of the knee joint.
Estonian: Käesoleval juhul hinnati Hyalograft C autografti kasutamist kõhredefektide parandamisel reieluu alumises otsas, kus reieluu moodustab osa põlveliigesest.
English: Hyalograft C autograft is a ‘combined advanced therapy product' as it incorporates a medical device (the scaffold).
Estonian: Hyalograft C autograft on kombineeritud uudne ravim, sest see sisaldab toote lahutamatu osana meditsiiniseadet (kõhrerakkude toes).
English: How does Hyalograft C autograft work?
Estonian: Milline on Hyalograft C autografti eeldatav toime?
English: officially notified the European Medicines Agency that it wishes to withdraw its application for a marketing authorisation for Hyalograft C autograft, for repairing defects in the cartilage of the femoral condyles and trochlea (the end of the thigh bone that forms part of the knee) caused by sudden or repetitive trauma.
Estonian: Ravim oli näidustatud reieluu põntade ja põntadevahelise ala (reieluu alumine ots, mis moodustab osa põlveliigesest) ägedast või kroonilisest traumast tingitud kõhredefektide raviks.
English: The standard dose of Clopidogrel Teva Pharma B.V. is one 75-mg tablet once a day, taken with or without food.
Estonian: tavaannus on üks 75 mg tablett üks kord ööpäevas, koos toiduga või ilma.
English: It is available as pink, capsule-shaped tablets (75 mg).
Estonian: Ravimit turustatakse roosade piklike tablettidena (75 mg).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Teva Pharma B.V.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a ‘non-Q-wave' myocardial infarction.
Estonian: Samuti tohib ravimit kasutada patsientidel, kellel seda ebanormaalset EKG-näitu ei ole, kui neil on ebastabiilne rinnaangiin (tugevad rindkerevalud) või on olnud Q-sakita südameinfarkt.
English: Because Clopidogrel Teva Pharma B.V. is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel Teva Pharma B.V. to Teva Pharma B.V. on 16 June 2011.
Estonian: müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Teva Pharma BV 16. juunil 2011.
English: For more information about treatment with Clopidogrel Teva Pharma B.V., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The full EPAR for Clopidogrel Teva Pharma B.V. can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: In acute coronary syndrome, Clopidogrel Teva Pharma B.V. is used together with aspirin and treatment generally starts with a loading dose of four tablets.
Estonian: koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse neli tabletti.
English: Clopidogrel Teva Pharma B.V. can be used in patients who are having a heart attack with ‘ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Estonian: tohib manustada ka patsientidele, kellel on ST-segmendi elevatsiooniga (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) südameinfarkt, kui arst arvab, et ravimist on patsiendile kasu.
English: This means that Clopidogrel Teva Pharma B.V. is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Estonian: manustada koos aspiriiniga (samuti antikoagulant), sealhulgas patsientidele, kellele on paigaldatud stent (ahenenud arterit avardav väike toru).
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel Teva Pharma B.V. has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Clopidogrel Teva Pharma B.V.
English: Clopidogrel Teva Pharma B.V. can be started between seven days and six months after the stroke;
Estonian: manustamist võib alustada 7 päeva kuni 6 kuu jooksul pärast insulti;
English: Clopidogrel Teva Pharma B.V. is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Estonian: kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide) ennetamiseks täiskasvanutel.
English: Other information about Clopidogrel Teva Pharma B.V.:
Estonian: Muu teave Ribavirin Clopidogrel Teva Pharma B.V.
English: Because Clopidogrel Teva Pharma B.V. is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Clopidogrel Teva Pharma B.V.
English: For genetic reasons, some patients may not be able to convert Clopidogrel Teva Pharma B.V. as effectively as others, which could reduce their response to the medicine.
Estonian: Geneetilistel põhjustel ei suuda kõikide patsientide organism ravimit Clopidogrel Teva Pharma B.V.
English: This document is a summary of the European public assessment report (EPAR) for Clopidogrel Teva Pharma B.V.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Clopidogrel Teva Pharma B.V.
English: What is Clopidogrel Teva Pharma B.V.?
Estonian: Mis on Clopidogrel Teva Pharma B.V.
English: The Committee recommended that Clopidogrel Teva Pharma B.V. be given marketing authorisation.
Estonian: Euroopa Komisjon andis Clopidogrel Teva Pharma B.V.
English: Why has Clopidogrel Teva Pharma B.V. been approved?
Estonian: Milleks kasutatakse ravimit Clopidogrel Teva Pharma B.V.
English: Route of administration Packaging Package size
Estonian: Pakendi iseloomustus Pakendi suurus
English: Invented name Strength Pharmaceutical form
Estonian: Müügiloa nr Euroopa Liidus Ravimi väljamõeldud nimetus Tugevus Ravimvorm
English: EU Number
Estonian: Manustamistee
English: Packaging size
Estonian: Pakendi suurus
English: Trade name
Estonian: Ravimi väljamõeldud nimetus
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 16 January, 2014
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV 16. jaanuar 2014
English: Elderly patients (≥ 65 years)
Estonian: Eakad patsiendid (≥ 65-aastased)
English: Xigduo with alcohol
Estonian: Xigduo koos alkoholiga
English: More information is given below in ‘Other medicines and Xigduo'.
Estonian: Rohkem teavet on esitatud allpool lõigus 'Muud ravimid ja Xigduo';
English: Xigduo is contraindicated in patients with:
Estonian: Xingduo on vastunäidustatud patsientidele, kel esineb:
English: You will need to tell your doctor and stop taking this medicine for a certain period of time and for 2 or more days after depending on how your kidneys are working.
Estonian: Te peate sellest rääkima oma arstile ja katkestama selle ravimi kasutamise teatud ajaks ja sellele järgnevaks kaheks või enamaks päevaks, olenevalt sellest, kuidas teie neerud töötavad.
English: • if you drink large amounts of alcohol, either every day or only from time to time (please see section “Xigduo with alcohol”).
Estonian: • kui te joote suures koguses alkoholi (kas iga päev või ainult aeg-ajalt) (vt lõiku 'Xigduo kasutamine koos alkoholiga').
English: Metformin1, b
Estonian: Metformiin1, b
English: It particularly effects patients whose kidneys are not working properly.
Estonian: Eriti võib see juhtuda patsientidega, kelle neerud ei tööta normaalselt.
English: Combination requiring precautions for use
Estonian: Kombinatsioonid, mille puhul on vajalik ettevaatusabinõude rakendamine
English: This is a build up of lactic acid in the blood that can cause death.
Estonian: See tähendab piimhappe moodustumist veres, mis võib lõppeda surmaga.
English: As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
Estonian: Kuna see ravim sisaldab metformiini, tuleb ravi katkestada 48 tundi enne plaanilist operatsiooni üld-, spinaal- või epiduraalanesteesias.
English: Make sure to ask your doctor for advice regarding when you can start your treatment again.
Estonian: Küsige kindlasti oma arstilt, millal te saate oma ravi jätkata.
English: See section 4.4
Estonian: k vt lõik 4.4.
English: • Prior to initiation of treatment and at least yearly thereafter (see sections 4.2, 4.8, 5.1 and 5.2)
Estonian: • enne ravi alustamist ning ravi ajal vähemalt üks kord aastas (vt lõik 4.2, 4.8, 5.1 ja 5.2);
English: Avoid alcohol, including medicines containing alcohol, while taking this medicine since alcohol may increase the risk of lactic acidosis (see section 4 ‘Possible side effects').
Estonian: Vältige selle ravimi kasutamise ajal alkoholi tarbimist, sh alkoholi sisaldavate ravimite kasutamist, kuna alkohol võib tõsta laktatsidoosi riski (vt lõik 4 'Võimalikud kõrvaltoimed').
English: Polyvinyl alcohol (E1203) Macrogol 3350 (E1520(iii)) Talc (E553b)
Estonian: Polüvinüülalkohol (E1203) Makrogool 3350 (E1520(iii)) Talk (E553b)
English: Metformin1 + Sitagliptin2
Estonian: Metformiin1 + Sitagliptiin2
English: Renal clearance of metformin is > 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Estonian: Metformiini renaalne kliirens on >400 ml/min, mis näitab, et metformiin elimineerub glomerulaarfiltratsiooni ja tubulaarsekretsiooni teel.
English: Your doctor may ask you to stop taking this medicine until you recover in order to prevent dehydration.
Estonian: Teie arst võib käskida teil katkestada ravi selle ravimiga, kuni teil nimetatud seisundid mööduvad, et ennetada dehüdratsiooni;
English: Vulvovaginitis, balanitis and related genital infections*,b,c
Estonian: Vulvovaginiit, balaniit ja nendega seotud genitaalinfektsioonid*,b,c Kuseteede infektsioon*,
English: If metabolic acidosis is suspected, treatment with the medicinal product should be discontinued and the patient hospitalised immediately (see section 4.9).
Estonian: Metaboolse atsidoosi kahtlusel tuleb ravi lõpetada ja patsient otsekohe hospitaliseerida (vt lõik 4.9).
English: If renal function falls below CrCl < 60 ml/min or eGFR < 60 ml/min/1.73 m2, treatment must be discontinued.
Estonian: Kui neerufunktsioon langeb alla CrCl < 60 ml/min või eGFR < 60 ml/min/1,73 m2, tuleb ravi katkestada.
English: bSee corresponding subsection below for additional information.
Estonian: b Täiendavaks informatsiooniks vt vastavat alalõiku allpool.
English: Lactic acidosis is a medical emergency and must be treated in hospital.
Estonian: Laktatsidoos on erakorralise meditsiini juhtum, mida tuleb ravida haiglas.
English: (95% CI) Mean daily insulin dose (IU)1
Estonian: (95% CI) Keskmine ööpäevane insuliini annus (RÜ)1
English: • if you have a condition called ‘diabetic ketoacidosis', a problem you can get with diabetes.
Estonian: • kui teil esineb seisund, mida nimetatakse diabeetiliseks ketoatsidoosiks - see on seisund, mis võib tekkida seoses suhkurtõvega.